 |
 |
|
|
NASTAD Press Release Regarding CDC's Revised HIV Incidence Estimates
|
NASTAD issued a press release on August 2, 2008 in reaction to the release of the Centers for Disease Control and Prevention's (CDC) revised HIV incidence estimates. Using new technologies to estimate HIV incidence, CDC now estimates that 56,300 new infections occurred in the U.S. in 2006, a number significantly higher than the previous estimate of 40,000 - a less precise count that had remained static for over a decade. The original release is published in the August 6, 2008 edition of the Journal of the American Medical Association (JAMA). NASTAD's Prevention Policy Agenda and background document Prevention Blueprint (see links below) provide concrete recommendations for addressing the HIV epidemic in the U.S. In addition, NASTAD's Executive Director, Julie Scofield, co-authored an op-ed in the Baltimore Sun with Dr. David Holtgrave, calling on renewed efforts in the fight against HIV/AIDS in the United States.
|
|
|
|
|
|
|
A New Blueprint for the Future: Ending the Epidemic Through the Power of Prevention -- November 2007
|
On November 29, 2007, NASTAD released A New Blueprint for the Nation: Ending the Epidemic Through the Power of Prevention, along with a companion policy agenda.
The Blueprint provides guideline for state and territorial health departments for ensuring they have the financial, political and programmatic resources necessary and in place to meaningfully scale up domestic HIV prevention efforts for the future.
|
|
|
NASTAD Prevention Policy Agenda -- November 2007
|
On November 29, 2007, NASTAD introduced a Prevention Policy Agenda to accompany its newly-released Blueprint, which includes recommendations for federal funding increases and expansion of core HIV/AIDS programs and services at the state and local levels.
|
|
|
|
|
Report on the Survey to Assess the Impact of Withdrawal of the HIV Oral Fluid Assay -- August 2007
|
Continuing efforts to make available important information and tools to support HIV testing, NASTAD has released a Report on the Survey to Assess the Impact of Withdrawal of the HIV Oral Fluid Assay. This report assesses the impact of the discontinuation of bioMérieux production of their HIV-1 serum and oral fluid Vironostika enzyme immunoassay (EIA) platforms in 2007. The report highlights health department plans for oral fluid HIV testing in light of the withdrawal of these products and the potential impact on HIV testing programs. NASTAD will use the findings to identify key areas for education and technical assistance across health departments and to identify important areas of advocacy with federal partners and the diagnostic manufacturers.
|
|
|
2007 Report on Findings from an Assessment of Health Department Efforts to Implement HIV Screening in Health Care Settings
|
NASTAD conducted this assessment to gain a better understanding of HIV testing programs at the state and local level. The report, released June 26, 2007, provides an in-depth analysis of the current legal and regulatory environments for HIV testing within states, current state and local health department efforts to support HIV screening in health care settings, and future state and local health department plans for implementation and/or expansion of HIV screening in health care settings. The report also examines the influence of the CDC's Revised Recommendations for HIV Testing of Adults, Adolescents and Pregnant Women in Health Care Settings on health department efforts to implement HIV screening.
|
|
|
Evidence-Based Interventions: Issues and Priorities for Health Departments -- April 2006
|
This issue brief explains the importance of EBIs in the prevention portfolio. It includes recommendations towards the goal of a long-term national plan in support of EBIs. It also includes profiles from several states that describe the implementation, adaptation and tailoring, training, and monitoring and quality assurance processes for EBIs in those states.
|
|
|
2006 Rapid HIV Test Assessment Report
|
NASTAD has long supported rapid HIV testing technology and was among those organizations instrumental in advocacy to obtain Food and Drug Administration (FDA) approval of rapid testing technology along with the Clinical Laboratory Improvement Amendments (CLIA) waiver that allowed their use without regulatory oversight, particularly in non-clinical settings. With the approval of this technology, health departments have implemented rapid testing in high-risk and other settings, resources permitting. Shortage of resources continues to further constrain implementation of rapid testing technology, in spite of the effectiveness and successes associated with it. In May 2006, as means to help guide policy and future HIV testing programs in the U.S., NASTAD conducted a survey of state and directly funded health departments.
|
|
|
|
|
|
|